User profiles for Colin S. Cooper
Colin CooperProfessor of Genetics, University of East Anglia Verified email at uea.ac.uk Cited by 109171 |
The Heidelberg classification of renal cell tumours
…, BJ Beckwith, P Bugert, CS Cooper… - The Journal of …, 1997 - Wiley Online Library
This paper presents the conclusions of a workshop entitled ‘Impact of Molecular Genetics
on the Classification of Renal Cell Tumours’, which was held in Heidelberg in October 1996. …
on the Classification of Renal Cell Tumours’, which was held in Heidelberg in October 1996. …
The evolutionary history of lethal metastatic prostate cancer
…, ICGC Prostate UK Group, DE Neal, CS Cooper… - Nature, 2015 - nature.com
Cancers emerge from an ongoing Darwinian evolutionary process, often leading to multiple
competing subclones within a single primary tumour 1 , 2 , 3 , 4 . This evolutionary process …
competing subclones within a single primary tumour 1 , 2 , 3 , 4 . This evolutionary process …
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Molecular cloning of the transforming gene from a chemically transformed human
osteosarcoma-derived cell line enables the gene to be mapped to chromosome 7 (7p11.4–7qter) …
osteosarcoma-derived cell line enables the gene to be mapped to chromosome 7 (7p11.4–7qter) …
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
…, V Martins, E Folkerd, J Clark, CS Cooper… - Journal of clinical …, 2008 - ascopubs.org
Purpose Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by
ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone …
ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone …
Multiple newly identified loci associated with prostate cancer susceptibility
…, C Ogden, C Fisher, C Jamieson, CS Cooper… - Nature …, 2008 - nature.com
Prostate cancer is the most common cancer affecting males in developed countries. It shows
consistent evidence of familial aggregation, but the causes of this aggregation are mostly …
consistent evidence of familial aggregation, but the causes of this aggregation are mostly …
Intragenic ERBB2 kinase mutations in tumours
The protein-kinase family is the most frequently mutated gene family found in human cancer
and faulty kinase enzymes are being investigated as promising targets for the design of …
and faulty kinase enzymes are being investigated as promising targets for the design of …
Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma
Human synovial sarcomas contain a recurrent and specific chromosomal translocation t(X;18)(p11.2;q11.2).
By screening a synovial sarcoma cDNA library with a yeast artificial …
By screening a synovial sarcoma cDNA library with a yeast artificial …
Mechanism of met oncogene activation
The met oncogene activated in vitro by treatment of a human osteogenic sarcoma (HOS) cell
line with N-methyl-N’-nitronitrosoguanidine(MNNG) is related to the tyrosine kinase gene …
line with N-methyl-N’-nitronitrosoguanidine(MNNG) is related to the tyrosine kinase gene …
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
…, A Thompson, T Dudderidge, C Ogden, CS Cooper… - Nature …, 2013 - nature.com
Prostate cancer is the most frequently diagnosed cancer in males in developed countries.
To identify common prostate cancer susceptibility alleles, we genotyped 211,155 SNPs on a …
To identify common prostate cancer susceptibility alleles, we genotyped 211,155 SNPs on a …
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
…, C Parker, D Dearnaley, SB Kaye, CS Cooper… - Cancer research, 2009 - AACR
Hormone-driven expression of the ERG oncogene after fusion with TMPRSS2 occurs in 30%
to 70% of therapy-naive prostate cancers. Its relevance in castration-resistant prostate …
to 70% of therapy-naive prostate cancers. Its relevance in castration-resistant prostate …